A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 21 Mar 2018 Planned End Date changed from 21 Mar 2021 to 21 Mar 2020.
- 18 May 2017 Planned End Date changed from 21 Mar 2020 to 21 Mar 2021.
- 09 Mar 2017 Status changed from not yet recruiting to recruiting.